aripiprazol +pharma 10 mg tabletten
+pharma arzneimittel gmbh - aripiprazol -
aripiprazol +pharma 15 mg tabletten
+pharma arzneimittel gmbh - aripiprazol -
aripiprazol +pharma 30 mg tabletten
+pharma arzneimittel gmbh - aripiprazol -
aripiprazol +pharma 5 mg tabletten
+pharma arzneimittel gmbh - aripiprazol -
blincyto
amgen europe b.v. - blinatumomab - vorläuferzelle lymphoblastische leukämie-lymphom - antineoplastische mittel - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.
sitagliptin +pharma 100 mg filmtabletten
+pharma arzneimittel gmbh - sitagliptin hydrochlorid monohydrat -
sitagliptin +pharma 25 mg filmtabletten
+pharma arzneimittel gmbh - sitagliptin hydrochlorid monohydrat -
sitagliptin +pharma 50 mg filmtabletten
+pharma arzneimittel gmbh - sitagliptin hydrochlorid monohydrat -
ibandronsäure +pharma 3 mg injektionslösung
+pharma arzneimittel gmbh - natrium ibandronat -
rasagilin +pharma 1 mg tabletten
+pharma arzneimittel gmbh - rasagilin hemitartrat -